Related Experiment Videos
Inhibition of neutrophil adhesion reduces myocardial infarct size
W E Curtis1, A M Gillinov, I C Wilson
1Department of Cardiac Surgery, Johns Hopkins Medical Institutions, Baltimore, Maryland.
Insights
NPC 15669, an anti-inflammatory agent, significantly reduced myocardial infarct size by 51% in a porcine model. This suggests inhibiting neutrophil adhesion is a promising strategy for treating heart attacks.
Area of Science:
- Cardiovascular Science
- Inflammation Research
- Pharmacology
Background:
- Neutrophil accumulation in the heart during ischemia and reperfusion contributes to myocardial stunning and infarction.
- Understanding the role of neutrophil adhesion in myocardial damage is crucial for developing therapeutic strategies.
Purpose of the Study:
- To investigate whether NPC 15669, a novel inhibitor of neutrophil adhesion, can reduce myocardial infarct size.
- To assess the efficacy of targeting neutrophil adhesion in a porcine model of ischemia-reperfusion injury.
Main Methods:
- A porcine model of transient left anterior descending artery occlusion and reperfusion was utilized.
- Animals received either NPC 15669 (anti-inflammatory agent inhibiting neutrophil adhesion) or saline control.
- Myocardial infarct size was quantified after the reperfusion period.
Main Results:
- No significant differences in hemodynamic parameters (rate-pressure product) or region at risk were observed between groups.
- NPC 15669 administration resulted in a 51% reduction in mean myocardial infarct size compared to controls (30.7% vs. 62.3%).
- The reduction in infarct size was statistically significant (p < 0.01).
Conclusions:
- NPC 15669 substantially reduces myocardial infarct size following transient ischemia and reperfusion.
- Inhibition of neutrophil adhesion to vascular endothelium appears to be a key factor in mitigating myocardial infarction pathogenesis.
- Targeting neutrophil adhesion presents a potential therapeutic approach for reducing heart attack damage.
Abstract:
Neutrophil accumulation and activation within the myocardium during ischemia and reperfusion has been shown to play a prominent role in the development of myocardial stunning and infarction. To determine if a simple inhibitor of neutrophil adhesion could reduce myocardial infarct size, we administered NPC 15669 (a new antiinflammatory agent that inhibits neutrophil adhesion) to 12 pigs (6 controls, 6 NPC-treated) in a porcine model of ischemia and reperfusion injury. Each animal received a continuous infusion of either NPC (10 mg/kg intravenous bolus followed by 6 mg.kg-1 x h-1 intravenous infusion) or an equal volume of normal saline solution during 1 hour of left anterior descending artery occlusion and 2 hours of reperfusion. There were no significant differences in the pre-ischemia, mid-ischemia, or postischemia rate-pressure product between control and experimental groups. The regions at risk were similar in both groups. However, the mean myocardial infarct size was reduced by 51% with administration of NPC 15669 (30.7% +/- 6.8%) compared with controls (62.3% +/- 5.4%; p < 0.01). These data indicate that NPC 15669, an inhibitor of neutrophil adhesion, substantially reduces myocardial infarct size after transient left anterior descending artery occlusion and that adhesion of the white cell to vascular endothelium may be an important element of the pathogenesis of myocardial infarction.